TG Therapeutics maps a shortcut to the FDA with lead drug for CLL
TG Therapeutics $TGTX will take a shot at shortening the Phase III runway for its lead effort on ublituximab (TG-1101).
The biotech, which has been …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
